+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Human Insulin Market By Product Type: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • PDF Icon

    Report

  • 245 Pages
  • July 2024
  • Region: Global
  • Allied Market Research
  • ID: 5994035
UP TO OFF until Jan 30th 2025
The human insulin market was valued at $17.1 billion in 2023 and is projected to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.

Human insulin is a synthetic mimic of the natural peptide hormone, which is synthesized in laboratory settings inside E. coli bacteria. It exists in two forms: a short-acting regular form and an intermediate-acting form known as neural protamine Hagedorn insulin. Human insulin replaces the naturally produced insulin inside the body and regulates the glucose levels in the blood.

A key driver of the human insulin market is increase in the prevalence of diabetes globally. In addition, human insulin is experiencing a surge in demand from patients and medical practitioners as compared to animal insulin owing to its high efficacy and minimal risk of allergic reactions. The latest trend in the human insulin market is the inclination of patients toward biosimilar products owing to their comparable efficacy and high cost-effectiveness.

However, the presence of other alternatives such as oral medications and non-insulin injectables, including GLP-1 receptor agonists, offers a significant competition to human insulin. Moreover, the introduction of human insulin into the market is a complex & time-consuming process due to the lengthy regulatory approval procedure at different stages, which include pre-clinical stages, clinical trials, and post-market safety monitoring. This delays the availability of the protein, thereby limiting the development of the market. On the contrary, the integration of data-driven approaches such as AI and machine learning is expected to speed up production efficiency by optimizing the production parameters and predicting product yields.

Segment Review

The human insulin market is segmented into product type, indication, type of insulin, distribution channel, and region. On the basis of product type, the market is divided into pens, syringes, and others. As per indication, it is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. Depending on type of insulin, it is categorized into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. According to distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the pens segment dominated the market in 2023.

As per indication, the type-1 diabetes segment acquired high stakes in the market in 2023.

Depending on type of insulin, the rapid-acting insulin segment garnered a high market share in 2023.

According to distribution channel, the drug stores & retail pharmacies segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players operating in the global human insulin market include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer, Biocon, Wockhardt, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Medtronic, and Lupin. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Pens
  • Syringes
  • Others

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By Type Of Insulin

  • Rapid-acting insulin
  • Short-acting insulin
  • Intermediate-acting insulin
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
Key Market Players
  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • Pfizer
  • Biocon
  • Wockhardt
  • MannKind Corporation
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Medtronic
  • Lupin

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product Type
4.2. Pens
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Syringes
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Others
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Type 1 Diabetes
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Type 2 Diabetes
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Gestational Diabetes
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN
6.1. Market Overview
6.1.1 Market Size and Forecast, By Type of Insulin
6.2. Rapid-acting Insulin
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Short-acting Insulin
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Intermediate-acting Insulin
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Others
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL
7.1. Market Overview
7.1.1 Market Size and Forecast, By Distribution Channel
7.2. Hospital Pharmacies
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Drug Stores And Retail Pharmacies
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Online Providers
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: HUMAN INSULIN MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Product Type
8.2.3. Market Size and Forecast, By Indication
8.2.4. Market Size and Forecast, By Type of Insulin
8.2.5. Market Size and Forecast, By Distribution Channel
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Human Insulin Market
8.2.7.1. Market Size and Forecast, By Product Type
8.2.7.2. Market Size and Forecast, By Indication
8.2.7.3. Market Size and Forecast, By Type of Insulin
8.2.7.4. Market Size and Forecast, By Distribution Channel
8.2.8. Canada Human Insulin Market
8.2.8.1. Market Size and Forecast, By Product Type
8.2.8.2. Market Size and Forecast, By Indication
8.2.8.3. Market Size and Forecast, By Type of Insulin
8.2.8.4. Market Size and Forecast, By Distribution Channel
8.2.9. Mexico Human Insulin Market
8.2.9.1. Market Size and Forecast, By Product Type
8.2.9.2. Market Size and Forecast, By Indication
8.2.9.3. Market Size and Forecast, By Type of Insulin
8.2.9.4. Market Size and Forecast, By Distribution Channel
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Product Type
8.3.3. Market Size and Forecast, By Indication
8.3.4. Market Size and Forecast, By Type of Insulin
8.3.5. Market Size and Forecast, By Distribution Channel
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Human Insulin Market
8.3.7.1. Market Size and Forecast, By Product Type
8.3.7.2. Market Size and Forecast, By Indication
8.3.7.3. Market Size and Forecast, By Type of Insulin
8.3.7.4. Market Size and Forecast, By Distribution Channel
8.3.8. France Human Insulin Market
8.3.8.1. Market Size and Forecast, By Product Type
8.3.8.2. Market Size and Forecast, By Indication
8.3.8.3. Market Size and Forecast, By Type of Insulin
8.3.8.4. Market Size and Forecast, By Distribution Channel
8.3.9. UK Human Insulin Market
8.3.9.1. Market Size and Forecast, By Product Type
8.3.9.2. Market Size and Forecast, By Indication
8.3.9.3. Market Size and Forecast, By Type of Insulin
8.3.9.4. Market Size and Forecast, By Distribution Channel
8.3.10. Italy Human Insulin Market
8.3.10.1. Market Size and Forecast, By Product Type
8.3.10.2. Market Size and Forecast, By Indication
8.3.10.3. Market Size and Forecast, By Type of Insulin
8.3.10.4. Market Size and Forecast, By Distribution Channel
8.3.11. Spain Human Insulin Market
8.3.11.1. Market Size and Forecast, By Product Type
8.3.11.2. Market Size and Forecast, By Indication
8.3.11.3. Market Size and Forecast, By Type of Insulin
8.3.11.4. Market Size and Forecast, By Distribution Channel
8.3.12. Rest of Europe Human Insulin Market
8.3.12.1. Market Size and Forecast, By Product Type
8.3.12.2. Market Size and Forecast, By Indication
8.3.12.3. Market Size and Forecast, By Type of Insulin
8.3.12.4. Market Size and Forecast, By Distribution Channel
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Product Type
8.4.3. Market Size and Forecast, By Indication
8.4.4. Market Size and Forecast, By Type of Insulin
8.4.5. Market Size and Forecast, By Distribution Channel
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Human Insulin Market
8.4.7.1. Market Size and Forecast, By Product Type
8.4.7.2. Market Size and Forecast, By Indication
8.4.7.3. Market Size and Forecast, By Type of Insulin
8.4.7.4. Market Size and Forecast, By Distribution Channel
8.4.8. China Human Insulin Market
8.4.8.1. Market Size and Forecast, By Product Type
8.4.8.2. Market Size and Forecast, By Indication
8.4.8.3. Market Size and Forecast, By Type of Insulin
8.4.8.4. Market Size and Forecast, By Distribution Channel
8.4.9. India Human Insulin Market
8.4.9.1. Market Size and Forecast, By Product Type
8.4.9.2. Market Size and Forecast, By Indication
8.4.9.3. Market Size and Forecast, By Type of Insulin
8.4.9.4. Market Size and Forecast, By Distribution Channel
8.4.10. Australia Human Insulin Market
8.4.10.1. Market Size and Forecast, By Product Type
8.4.10.2. Market Size and Forecast, By Indication
8.4.10.3. Market Size and Forecast, By Type of Insulin
8.4.10.4. Market Size and Forecast, By Distribution Channel
8.4.11. South Korea Human Insulin Market
8.4.11.1. Market Size and Forecast, By Product Type
8.4.11.2. Market Size and Forecast, By Indication
8.4.11.3. Market Size and Forecast, By Type of Insulin
8.4.11.4. Market Size and Forecast, By Distribution Channel
8.4.12. Rest of Asia-Pacific Human Insulin Market
8.4.12.1. Market Size and Forecast, By Product Type
8.4.12.2. Market Size and Forecast, By Indication
8.4.12.3. Market Size and Forecast, By Type of Insulin
8.4.12.4. Market Size and Forecast, By Distribution Channel
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Product Type
8.5.3. Market Size and Forecast, By Indication
8.5.4. Market Size and Forecast, By Type of Insulin
8.5.5. Market Size and Forecast, By Distribution Channel
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Human Insulin Market
8.5.7.1. Market Size and Forecast, By Product Type
8.5.7.2. Market Size and Forecast, By Indication
8.5.7.3. Market Size and Forecast, By Type of Insulin
8.5.7.4. Market Size and Forecast, By Distribution Channel
8.5.8. Saudi Arabia Human Insulin Market
8.5.8.1. Market Size and Forecast, By Product Type
8.5.8.2. Market Size and Forecast, By Indication
8.5.8.3. Market Size and Forecast, By Type of Insulin
8.5.8.4. Market Size and Forecast, By Distribution Channel
8.5.9. South Africa Human Insulin Market
8.5.9.1. Market Size and Forecast, By Product Type
8.5.9.2. Market Size and Forecast, By Indication
8.5.9.3. Market Size and Forecast, By Type of Insulin
8.5.9.4. Market Size and Forecast, By Distribution Channel
8.5.10. Rest of LAMEA Human Insulin Market
8.5.10.1. Market Size and Forecast, By Product Type
8.5.10.2. Market Size and Forecast, By Indication
8.5.10.3. Market Size and Forecast, By Type of Insulin
8.5.10.4. Market Size and Forecast, By Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Eli Lilly And Company
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Sanofi
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Novo Nordisk A/S
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Pfizer
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Biocon
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Wockhardt
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. MannKind Corporation
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Medtronic
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Lupin
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
LIST OF TABLES
Table 1. Global Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 2. Human Insulin Market for Pens, by Region, 2024 - 2033 ($Billion)
Table 3. Human Insulin Market for Syringes, by Region, 2024 - 2033 ($Billion)
Table 4. Human Insulin Market for Others, by Region, 2024 - 2033 ($Billion)
Table 5. Global Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 6. Human Insulin Market for Type 1 Diabetes, by Region, 2024 - 2033 ($Billion)
Table 7. Human Insulin Market for Type 2 Diabetes, by Region, 2024 - 2033 ($Billion)
Table 8. Human Insulin Market for Gestational Diabetes, by Region, 2024 - 2033 ($Billion)
Table 9. Global Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 10. Human Insulin Market for Rapid-Acting Insulin, by Region, 2024 - 2033 ($Billion)
Table 11. Human Insulin Market for Short-Acting Insulin, by Region, 2024 - 2033 ($Billion)
Table 12. Human Insulin Market for Intermediate-Acting Insulin, by Region, 2024 - 2033 ($Billion)
Table 13. Human Insulin Market for Others, by Region, 2024 - 2033 ($Billion)
Table 14. Global Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 15. Human Insulin Market for Hospital Pharmacies, by Region, 2024 - 2033 ($Billion)
Table 16. Human Insulin Market for Drug Stores and Retail Pharmacies, by Region, 2024 - 2033 ($Billion)
Table 17. Human Insulin Market for Online Providers, by Region, 2024 - 2033 ($Billion)
Table 18. Human Insulin Market, by Region, 2024 - 2033 ($Billion)
Table 19. North America Human Insulin Market, by Country, 2024 - 2033 ($Billion)
Table 20. North America Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 21. North America Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 22. North America Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 23. North America Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 24. U.S. Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 25. U.S. Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 26. U.S. Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 27. U.S. Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 28. Canada Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 29. Canada Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 30. Canada Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 31. Canada Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 32. Mexico Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 33. Mexico Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 34. Mexico Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 35. Mexico Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 36. Europe Human Insulin Market, by Country, 2024 - 2033 ($Billion)
Table 37. Europe Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 38. Europe Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 39. Europe Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 40. Europe Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 41. Germany Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 42. Germany Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 43. Germany Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 44. Germany Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 45. France Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 46. France Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 47. France Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 48. France Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 49. UK Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 50. UK Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 51. UK Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 52. UK Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 53. Italy Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 54. Italy Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 55. Italy Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 56. Italy Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 57. Spain Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 58. Spain Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 59. Spain Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 60. Spain Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 61. Rest of Europe Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 62. Rest of Europe Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 63. Rest of Europe Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 64. Rest of Europe Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 65. Asia-Pacific Human Insulin Market, by Country, 2024 - 2033 ($Billion)
Table 66. Asia-Pacific Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 67. Asia-Pacific Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 68. Asia-Pacific Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 69. Asia-Pacific Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 70. Japan Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 71. Japan Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 72. Japan Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 73. Japan Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 74. China Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 75. China Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 76. China Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 77. China Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 78. India Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 79. India Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 80. India Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 81. India Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 82. Australia Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 83. Australia Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 84. Australia Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 85. Australia Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 86. South Korea Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 87. South Korea Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 88. South Korea Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 89. South Korea Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 90. Rest of Asia-Pacific Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 91. Rest of Asia-Pacific Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 92. Rest of Asia-Pacific Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 93. Rest of Asia-Pacific Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 94. LAMEA Human Insulin Market, by Country, 2024 - 2033 ($Billion)
Table 95. LAMEA Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 96. LAMEA Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 97. LAMEA Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 98. LAMEA Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 99. Brazil Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 100. Brazil Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 101. Brazil Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 102. Brazil Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 103. Saudi Arabia Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 104. Saudi Arabia Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 105. Saudi Arabia Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 106. Saudi Arabia Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 107. South Africa Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 108. South Africa Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 109. South Africa Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 110. South Africa Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 111. Rest of LAMEA Human Insulin Market, by Product Type, 2024 - 2033 ($Billion)
Table 112. Rest of LAMEA Human Insulin Market, by Indication, 2024 - 2033 ($Billion)
Table 113. Rest of LAMEA Human Insulin Market, by Type of Insulin, 2024 - 2033 ($Billion)
Table 114. Rest of LAMEA Human Insulin Market, by Distribution Channel, 2024 - 2033 ($Billion)
Table 115. Eli Lilly and Company: Key Executives
Table 116. Eli Lilly and Company: Company Snapshot
Table 117. Eli Lilly and Company: Operating Segments
Table 118. Eli Lilly and Company: Product Portfolio
Table 119. Eli Lilly and Company: Key Strategic Moves and Developments
Table 120. Sanofi: Key Executives
Table 121. Sanofi: Company Snapshot
Table 122. Sanofi: Operating Segments
Table 123. Sanofi: Product Portfolio
Table 124. Sanofi: Key Strategic Moves and Developments
Table 125. Novo Nordisk A/S: Key Executives
Table 126. Novo Nordisk A/S: Company Snapshot
Table 127. Novo Nordisk A/S: Operating Segments
Table 128. Novo Nordisk A/S: Product Portfolio
Table 129. Novo Nordisk A/S: Key Strategic Moves and Developments
Table 130. Pfizer: Key Executives
Table 131. Pfizer: Company Snapshot
Table 132. Pfizer: Operating Segments
Table 133. Pfizer: Product Portfolio
Table 134. Pfizer: Key Strategic Moves and Developments
Table 135. Biocon: Key Executives
Table 136. Biocon: Company Snapshot
Table 137. Biocon: Operating Segments
Table 138. Biocon: Product Portfolio
Table 139. Biocon: Key Strategic Moves and Developments
Table 140. Wockhardt: Key Executives
Table 141. Wockhardt: Company Snapshot
Table 142. Wockhardt: Operating Segments
Table 143. Wockhardt: Product Portfolio
Table 144. Wockhardt: Key Strategic Moves and Developments
Table 145. Mannkind Corporation: Key Executives
Table 146. Mannkind Corporation: Company Snapshot
Table 147. Mannkind Corporation: Operating Segments
Table 148. Mannkind Corporation: Product Portfolio
Table 149. Mannkind Corporation: Key Strategic Moves and Developments
Table 150. Tonghua Dongbao Pharmaceutical Co. Ltd.: Key Executives
Table 151. Tonghua Dongbao Pharmaceutical Co. Ltd.: Company Snapshot
Table 152. Tonghua Dongbao Pharmaceutical Co. Ltd.: Operating Segments
Table 153. Tonghua Dongbao Pharmaceutical Co. Ltd.: Product Portfolio
Table 154. Tonghua Dongbao Pharmaceutical Co. Ltd.: Key Strategic Moves and Developments
Table 155. Medtronic: Key Executives
Table 156. Medtronic: Company Snapshot
Table 157. Medtronic: Operating Segments
Table 158. Medtronic: Product Portfolio
Table 159. Medtronic: Key Strategic Moves and Developments
Table 160. Lupin: Key Executives
Table 161. Lupin: Company Snapshot
Table 162. Lupin: Operating Segments
Table 163. Lupin: Product Portfolio
Table 164. Lupin: Key Strategic Moves and Developments
LIST OF FIGURES
Figure 1. Global Human Insulin Market, 2024 - 2033
Figure 2. Segmentation of Human Insulin Market, 2024 - 2033
Figure 3. Top Investment Pocket in Human Insulin Market
Figure 4. Moderate Bargaining Power of Buyers
Figure 5. Moderate Bargaining Power of Suppliers
Figure 6. Moderate Threat of New Entrants
Figure 7. Low Threat of Substitution
Figure 8. High Competitive Rivalry
Figure 9. Opportunities, Restraints and Drivers: Globalhuman Insulin Market
Figure 10. Global Human Insulin Market Segmentation, by Product Type
Figure 11. Human Insulin Market for Pens, by Country, 2024 - 2033 ($Billion)
Figure 12. Human Insulin Market for Syringes, by Country, 2024 - 2033 ($Billion)
Figure 13. Human Insulin Market for Others, by Country, 2024 - 2033 ($Billion)
Figure 14. Global Human Insulin Market Segmentation, by Indication
Figure 15. Human Insulin Market for Type 1 Diabetes, by Country, 2024 - 2033 ($Billion)
Figure 16. Human Insulin Market for Type 2 Diabetes, by Country, 2024 - 2033 ($Billion)
Figure 17. Human Insulin Market for Gestational Diabetes, by Country, 2024 - 2033 ($Billion)
Figure 18. Global Human Insulin Market Segmentation, by Type of Insulin
Figure 19. Human Insulin Market for Rapid-Acting Insulin, by Country, 2024 - 2033 ($Billion)
Figure 20. Human Insulin Market for Short-Acting Insulin, by Country, 2024 - 2033 ($Billion)
Figure 21. Human Insulin Market for Intermediate-Acting Insulin, by Country, 2024 - 2033 ($Billion)
Figure 22. Human Insulin Market for Others, by Country, 2024 - 2033 ($Billion)
Figure 23. Global Human Insulin Market Segmentation, by Distribution Channel
Figure 24. Human Insulin Market for Hospital Pharmacies, by Country, 2024 - 2033 ($Billion)
Figure 25. Human Insulin Market for Drug Stores and Retail Pharmacies, by Country, 2024 - 2033 ($Billion)
Figure 26. Human Insulin Market for Online Providers, by Country, 2024 - 2033 ($Billion)
Figure 27. Top Winning Strategies, by Year, 2021-2023*
Figure 28. Top Winning Strategies, by Development, 2021-2023*
Figure 29. Top Winning Strategies, by Company, 2021-2023*
Figure 30. Product Mapping of Top 10 Players
Figure 31. Competitive Dashboard
Figure 32. Competitive Heatmap: Human Insulin Market
Figure 33. Top Player Positioning, 2023
Figure 34. Eli Lilly and Company: Net Sales, 2021-2023 ($Billion)
Figure 35. Eli Lilly and Company: Revenue Share, by Segment, 2023 (%)
Figure 36. Eli Lilly and Company: Revenue Share, by Region, 2023 (%)
Figure 37. Sanofi: Net Sales, 2021-2023 ($Billion)
Figure 38. Sanofi: Revenue Share, by Segment, 2023 (%)
Figure 39. Sanofi: Revenue Share, by Region, 2023 (%)
Figure 40. Novo Nordisk A/S: Net Sales, 2021-2023 ($Billion)
Figure 41. Novo Nordisk A/S: Revenue Share, by Segment, 2023 (%)
Figure 42. Novo Nordisk A/S: Revenue Share, by Region, 2023 (%)
Figure 43. Pfizer: Net Sales, 2021-2023 ($Billion)
Figure 44. Pfizer: Revenue Share, by Segment, 2023 (%)
Figure 45. Pfizer: Revenue Share, by Region, 2023 (%)
Figure 46. Biocon: Net Sales, 2021-2023 ($Billion)
Figure 47. Biocon: Revenue Share, by Segment, 2023 (%)
Figure 48. Biocon: Revenue Share, by Region, 2023 (%)
Figure 49. Wockhardt: Net Sales, 2021-2023 ($Billion)
Figure 50. Wockhardt: Revenue Share, by Segment, 2023 (%)
Figure 51. Wockhardt: Revenue Share, by Region, 2023 (%)
Figure 52. Mannkind Corporation: Net Sales, 2021-2023 ($Billion)
Figure 53. Mannkind Corporation: Revenue Share, by Segment, 2023 (%)
Figure 54. Mannkind Corporation: Revenue Share, by Region, 2023 (%)
Figure 55. Tonghua Dongbao Pharmaceutical Co. Ltd.: Net Sales, 2021-2023 ($Billion)
Figure 56. Tonghua Dongbao Pharmaceutical Co. Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 57. Tonghua Dongbao Pharmaceutical Co. Ltd.: Revenue Share, by Region, 2023 (%)
Figure 58. Medtronic: Net Sales, 2021-2023 ($Billion)
Figure 59. Medtronic: Revenue Share, by Segment, 2023 (%)
Figure 60. Medtronic: Revenue Share, by Region, 2023 (%)
Figure 61. Lupin: Net Sales, 2021-2023 ($Billion)
Figure 62. Lupin: Revenue Share, by Segment, 2023 (%)
Figure 63. Lupin: Revenue Share, by Region, 2023 (%)

Companies Mentioned

Key Market Players in the Human Insulin Market include:
  • Eli Lilly and Company
  • Sanofi
Novo Nordisk A/S
  • Pfizer
  • Biocon
  • Wockhardt
  • MannKind Corporation
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Medtronic
  • Lupin

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information